Showing results (221-230 of 229) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 229 results.
Microbial Cell Factories|November 25, 2010
Identification and characterization of a novel fumarase gene by metagenome expression cloning from marine microorganismsChengjian Jiang, Lan-Lan Wu, Gao-Chao Zhao, et al.
EMBO Reports|May 20, 2022
Myeloid cell-specific topoisomerase 1 inhibition using DNA origami mitigates neuroinflammationKeying Zhu, Yang Wang, Heela Sarlus, et al.
Nature Immunology|April 18, 2018
Fatal demyelinating disease is induced by monocyte-derived macrophages in the absence of TGF-β signalingHarald Lund, Melanie Pieber, Roham Parsa, et al.
Journal of Neuroinflammation|January 22, 2022
An overlooked subset of Cx3cr1<sup>wt/wt</sup> microglia in the Cx3cr1<sup>CreER-Eyfp/wt</sup> mouse has a repopulation advantage over Cx3cr1<sup>CreER-Eyfp/wt</sup> microglia following microglial depletionKai Zhou, Jinming Han, Harald Lund, et al.
Journal of Medical Case Reports|December 10, 2022
Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case reportBai-Yan Wang, Wan-Hong Zhao, Yin-Xia Chen, et al.
Science China. Life Sciences|June 25, 2019
Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young womenYue-Mei Hu, Meng Guo, Chang-Gui Li, et al.
Journal of Hematology & Oncology|December 22, 2018
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myelomaWan-Hong Zhao, Jie Liu, Bai-Yan Wang, et al.
Journal of Hematology & Oncology|July 6, 2022
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)Wan-Hong Zhao, Bai-Yan Wang, Li-Juan Chen, et al.
The Lancet. Infectious Diseases|August 29, 2022
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trialFang-Hui Zhao, Ting Wu, Yue-Mei Hu, et al.
Pageof 23